Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RMD open

Showing results (31-40 of 2,081) with videos related to

Pageof 209
Sort By:
RMD Open|January 19, 2024
Correction: Personalised care packages for people with rheumatoid arthritis: a mixed-methods study
RMD Open|September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorsPeter Nash, Frank Behrens, Ana-Maria Orbai, et al.
RMD Open|April 17, 2024
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up periodJessica Polo Y La Borda, Santos Castañeda, Elena Heras-Recuero, et al.
RMD Open|March 1, 2016
Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED studyGülşah Akdemir, Marije K Verheul, Lotte Heimans, et al.
RMD Open|March 1, 2016
Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 studyYoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, et al.
RMD Open|April 22, 2016
Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trialG Akdemir, I M Markusse, L Dirven, et al.
RMD Open|April 22, 2016
Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohortStephanie Harvard, Daphne Guh, Nick Bansback, et al.
RMD Open|June 3, 2016
Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseasesShaun M Flint, Vojislav Jovanovic, Boon Wee Teo, et al.
RMD Open|June 3, 2016
Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain SetVivian P Bykerk, Clifton O Bingham, Ernest H Choy, et al.
RMD Open|June 3, 2016
Bakers' cyst and tibiofemoral abnormalities are more distinctive MRI features of symptomatic osteoarthritis than patellofemoral abnormalitiesA W Visser, B Mertens, M Reijnierse, et al.
Pageof 209

Showing results (31-40 of 2,081) with videos related to

Sort By:
Pageof 209
RMD Open|January 19, 2024
Correction: Personalised care packages for people with rheumatoid arthritis: a mixed-methods study
RMD Open|September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorsPeter Nash, Frank Behrens, Ana-Maria Orbai, et al.
RMD Open|April 17, 2024
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up periodJessica Polo Y La Borda, Santos Castañeda, Elena Heras-Recuero, et al.
RMD Open|March 1, 2016
Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED studyGülşah Akdemir, Marije K Verheul, Lotte Heimans, et al.
RMD Open|March 1, 2016
Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 studyYoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, et al.
RMD Open|April 22, 2016
Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trialG Akdemir, I M Markusse, L Dirven, et al.
RMD Open|April 22, 2016
Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohortStephanie Harvard, Daphne Guh, Nick Bansback, et al.
RMD Open|June 3, 2016
Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseasesShaun M Flint, Vojislav Jovanovic, Boon Wee Teo, et al.
RMD Open|June 3, 2016
Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain SetVivian P Bykerk, Clifton O Bingham, Ernest H Choy, et al.
RMD Open|June 3, 2016
Bakers' cyst and tibiofemoral abnormalities are more distinctive MRI features of symptomatic osteoarthritis than patellofemoral abnormalitiesA W Visser, B Mertens, M Reijnierse, et al.
Pageof 209